Complement activation and thromboxane secretion by liposome-encapsulated hemoglobin in rats in vivo: Inhibition by soluble complement receptor type 1

Janos Szebeni, Helmut Spielberg, Richard O. Cliff, Nabila M. Wassef, Alan S. Rudolph, Carl R. Alving

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Intravenous administration of liposome-encapsulated hemoglobin (LEH) in rats led to an early (within 15 min) decline of hemolytic complement (C) activity in the plasma along with a significant, parallel rise in thromboxane B2 (TXB2) levels. The TXB2 response was inhibited by co-administration of soluble C receptor type 1 (sCR1) with LEH, as well as by C depletion with cobra venom factor. These observations provide evidence for a causal relationship between LEH-induced C activation and TXB2 release, and suggest that sCR1 could be useful in attenuating the acute respiratory, hematological and hemodynamic side effects of LEH described earlier in the rat.

Original languageEnglish
Pages (from-to)347-355
Number of pages9
JournalArtificial Cells, Blood Substitutes, and Immobilization Biotechnology
Volume25
Issue number4
DOIs
Publication statusPublished - Jan 1 1997

ASJC Scopus subject areas

  • Biotechnology
  • Biomedical Engineering

Fingerprint Dive into the research topics of 'Complement activation and thromboxane secretion by liposome-encapsulated hemoglobin in rats in vivo: Inhibition by soluble complement receptor type 1'. Together they form a unique fingerprint.

  • Cite this